<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pathologic response induced preoperatively is a mechanism-linked surrogate of systemic immune control unique to immunotherapy - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-24</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-24</p>
                <p><strong>Name:</strong> Pathologic response induced preoperatively is a mechanism-linked surrogate of systemic immune control unique to immunotherapy</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> Pathologic tumor regression achieved during neoadjuvant immunotherapy reflects successful systemic antitumor immunity and predicts durable relapse control, enabling response-directed de-escalation of surgery/adjuvant therapy. This surrogate relationship is modality-specific: similar depth of regression after targeted therapy does not confer the same durability.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Digitized quantification of viable tumor plus immune-infiltrate metrics in the index node will further stratify relapse risk within MPR.</li>
                <li>Pathologic responders to perioperative LAG-3+PD-1 will show RFS similar to MPR after CTLA-4+PD-1, validating class effect of immunotherapy-induced MPR.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>A single adjuvant PD-1 consolidation dose in MPR patients will not improve RFS but may increase toxicity; a non-inferiority trial could confirm omission.</li>
                <li>For pPR patients, adding short-course adjuvant PD-1 or BRAF/MEK (if mutant) may rescue outcomes to near-MPR levels; magnitude uncertain.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If randomized omission of adjuvant PD-1 in MPR leads to inferior EFS vs continuation, the de-escalation principle would be refuted.</li>
                <li>If neoadjuvant targeted therapy pCR leads to equal durability as immunotherapy pCR in randomized settings, modality specificity would be weakened.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Heterogeneity of pPR prognostic value between OpACIN-neo and PRADO suggests unmeasured confounders (e.g., sampling error, biology) not captured by current thresholds. <a href="../results/extraction-result-18.html#e18.3" class="evidence-link">[e18.3]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>